This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Other Nontraumatic Intracranial Haemorrhage — Acute Intensive Care, V268기타 비외상성 두개내출혈 — 급성기 집중치료

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: I62 (Other nontraumatic intracranial haemorrhage) | Special Copayment Reduction: V268 (Special copayment reduction for acute-phase intensive care of cerebrovascular disease: intensive care unit admission, 5% copayment for up to 30 days)
B. SynonymsNontraumatic subdural hematoma (acute/subacute/chronic SDH), nontraumatic epidural hematoma, nontraumatic intracranial hemorrhage, unspecified (I62.9); spontaneous subdural hematoma, nontraumatic extradural hemorrhage
C. Adult onsetNontraumatic subdural hematoma commonly occurs in patients of advanced age (≥60 years), those taking anticoagulants, and those with brain atrophy, and can appear in various age groups.
1. HistorySummarizes the history of I62 treatment, from the first description of subdural hematoma to twist-drill craniostomy and craniotomy and the development of minimally invasive surgery.
2. CausesAnticoagulants and antiplatelet agents, brain atrophy (advanced age), coagulation disorders, dural AVF, intracranial hypotension (low CSF pressure), and tumor metastasis are the main causes of nontraumatic subdural hematoma.
3. GeneticsMost are acquired, but CADASIL (NOTCH3), COL4A1 mutations, and inherited coagulation factor abnormalities are involved in a minority.
4. General epidemiologyIncidence of chronic subdural hematoma: about 13–58 per 100,000 population aged 65 or older; it is rising rapidly with increasing age and anticoagulant use.
5. PathophysiologyPathophysiology of bridging vein microbleeding → subdural blood accumulation → gradual expansion through increased hematoma osmotic pressure and rebleeding → nerve compression.
6. SymptomsHeadache, cognitive decline, gait disturbance, hemiparesis, altered consciousness; in the chronic form they appear gradually over weeks, and diagnosis is easily delayed.
7. SignsHemiparesis, speech disturbance, altered mental status, pupillary abnormalities; in elderly patients, differentiation from dementia or normal pressure hydrocephalus is necessary.
8. ScreeningNon-contrast CT is first-line; acute/subacute/chronic are distinguished by the crescent-shaped hyper-, iso-, or hypodense pattern of the hematoma.
9. DiagnosisAfter confirmation by CT, staging and complications are evaluated by MRI (FLAIR, T1, T2); if the cause is unknown, vascular malformations are excluded by CTA or DSA.
10. TreatmentSymptomatic or large hematomas are drained by burr-hole craniostomy, craniotomy, or minimally invasive surgery; dexamethasone as adjunctive therapy; small asymptomatic hematomas are observed.
11. PrognosisFunctional recovery rate after surgery about 80–90%; recurrence rate about 10–20%; chronic subdural hematoma mostly has a favorable prognosis with treatment.
12. PreventionAppropriate anticoagulant management, fall prevention, and correction of the cause of intracranial hypotension (low CSF pressure) are the key preventive strategies.
13. ReferencesEdlmann E et al. Pathophysiology of chronic subdural haematoma … and 9 other papers

1. History

Other nontraumatic intracranial hemorrhages classified under I62 include the nontraumatic (spontaneous) forms of subdural hemorrhage (SDH) and extradural hemorrhage, of which spontaneous/nontraumatic subdural hematoma is the most clinically important.

The history of subdural hematoma goes back to descriptions of blood accumulation in the head even in ancient texts, but the first systematic descriptions of subdural hematoma in its modern sense are found in the autopsy reports of Johann Jakob Wepfer in the 17th century and Giovanni Battista Morgagni in the 18th century. In the 19th century, Rudolf Virchow (1857) named chronic subdural hematoma 'pachymeningitis hemorrhagica interna', described its histologic features, and described the process of capsule formation with an inner membrane and an outer membrane.

In 1925, Putnam and Cushing systematized the pathophysiology of chronic subdural hematoma and proposed the osmotic theory—the theory that as osmotic pressure rises due to protein breakdown within the hematoma, cerebrospinal fluid flows into the hematoma and the hematoma expands. This theory is still partly valid, but neovascularization and repeated microbleeding are now recognized as more important mechanisms of expansion. In the 1960s–1970s, as burr-hole drainage became standardized, surgical outcomes improved greatly.

The introduction of CT (1973) made noninvasive diagnosis of subdural hematoma possible, and it became possible to distinguish acute, subacute, and chronic hematomas by their CT attenuation characteristics. The introduction of MRI enabled more accurate staging and evaluation of internal septation and rebleeding findings. Recently, middle meningeal artery embolization has attracted attention as a new treatment for preventing recurrence of chronic subdural hematoma, and large studies on MMA embolization are under way. In the 2020s, randomized controlled studies on the effect of dexamethasone (DRESH, etc.) have been published, establishing evidence for nonsurgical treatment.


2. Causes

The causes of nontraumatic intracranial hemorrhage (I62) vary by type.

Causes of nontraumatic SDH: cases in which blood accumulates spontaneously in the subdural space without trauma. The main causes are ① anticoagulants and antiplatelet agents (warfarin, DOACs, aspirin): one of the most common causes; these drugs are frequently involved in SDH in elderly patients. ② Cerebral atrophy: with brain atrophy due to advanced age or alcohol dependence, bridging veins are stretched and become fragile, and SDH forms through minor trauma or spontaneous rupture. ③ Coagulation disorders: include thrombocytopenia, liver failure (coagulation factor deficiency), leukemia, etc. ④ Spontaneous intracranial hypotension: the brain descends due to CSF leakage, and bridging veins are excessively pulled and rupture. It is characterized by headache that worsens on standing. ⑤ Dural AVF: abnormal connections of dural vessels can cause SDH. ⑥ Meningioma and metastatic tumors: spontaneous bleeding from tumors adjacent to the dura causes SDH. Nontraumatic EDH is rare and is caused by bone vascular malformations, coagulation disorders, epidural vascular malformations, or nontraumatic bone tumors or metastases.


3. Genetics

Most nontraumatic intracranial hemorrhage (I62) is due to acquired causes, and cases directly involving a specific single-gene cause are a minority.

CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) is an autosomal dominant inherited cerebral small vessel disease caused by mutations in the NOTCH3 (19p13) gene. In patients with CADASIL, various intracranial hemorrhages (subdural, intracerebral) can occur due to small vessel fragility. With COL4A1/COL4A2 gene variants, the vessel wall is weakened by defects in type IV collagen of the cerebral basement membrane, and various intracranial hemorrhages, including subdural hematoma, can occur.

In inherited coagulation factor abnormalities—hemophilia A (F8 gene), hemophilia B (F9 gene), von Willebrand disease (VWF gene)—the risk of spontaneous bleeding, including subdural hematoma, is increased. In patients with hemophilia, intracranial hemorrhage is a serious, life-threatening complication. Inherited diseases causing platelet dysfunction—Glanzmann thrombasthenia (ITGA2B/ITGB3), Bernard-Soulier syndrome (GP1BA/GP1BB/GP9)—also carry a risk of spontaneous intracranial hemorrhage. Overall, when a genetic cause is suspected in nontraumatic SDH, coagulation factor, platelet function, and related genetic tests are performed selectively.


4. General epidemiology

The epidemiology of nontraumatic intracranial hemorrhage (I62) differs by the type of lesion included.

Chronic subdural hematoma (CSDH) is emerging as one of the most common neurosurgical emergencies in the elderly population. An incidence of about 13–58 per 100,000 population aged 65 or older has been reported, and the incidence is rising rapidly with population aging and increasing anticoagulant use. Among all intracranial hematomas, chronic subdural hematoma is becoming the most common single indication for neurosurgical surgery. It tends to be slightly more common in men (male:female = about 2:1), because fall- and alcohol-related cases are more common in men.

Acute SDH is mostly traumatic, and nontraumatic acute SDH is relatively rare (about 1–5% of all SDH). Nontraumatic causes include anticoagulant-related cases, spontaneous intracranial hypotension, and ruptured cerebral aneurysm. Nontraumatic epidural hematoma is very rare, accounting for less than 1–2% of all intracranial hematomas, and is caused by various conditions such as coagulation disorders, dural vascular malformations, Paget disease, and hemangioblastoma. Anticoagulant-related intracranial hemorrhage (including I62) continues to grow in importance overall with the increase in oral anticoagulant prescriptions—especially the growth of the atrial fibrillation population.


5. Pathophysiology

The pathogenesis of nontraumatic subdural hematoma is conceptually similar to that of traumatic SDH but differs in that the initial triggering factor is not trauma.

Bridging vein rupture is the key mechanism of SDH formation. Bridging veins running from the cerebral cortex to the superior sagittal sinus have vulnerable segments where they pass beneath the dura. When the brain moves away from the skull due to brain atrophy, the bridging veins are pulled longer and tighter, making spontaneous rupture easier. If hemostasis is insufficient due to anticoagulants or reduced platelet function, a small bleed does not stop and forms a hematoma.

Mechanism of chronicity: when the initial bleed clots in the subdural space, a hematoma capsule forms around it. Neovascularization of the hematoma capsule and repeated microbleeding from these new vessels, gradually expanding the hematoma, is currently recognized as the most important pathogenetic theory. VEGF is overexpressed in the hematoma capsule, leading to the incomplete structure and high permeability of the new vessels. Coagulation products within the hematoma—thrombin, fibrin degradation products—form a vicious cycle that promotes inflammation and neovascularization.

The mechanism of SDH related to intracranial hypotension is that the decrease in intracranial CSF volume due to CSF leakage causes the brain to descend in the direction of gravity (brain sagging), so that the bridging veins are excessively pulled and rupture. In nontraumatic epidural hematoma, the mechanism is rupture of an epidural vascular malformation, erosion by a vessel-invading lesion, or spontaneous bleeding from the epidural venous plexus due to coagulopathy.


6. Symptoms

The symptoms of nontraumatic intracranial hemorrhage (I62) vary according to the hematoma type (acute/subacute/chronic), size, location, and underlying cause.

In chronic subdural hematoma, symptoms develop gradually over weeks, so diagnosis is often delayed. The most common symptom is headache (about 50–80%), and worsening on standing suggests concomitant intracranial hypotension. Cognitive decline—reduced memory, impaired judgment, decreased concentration—is often mistaken for dementia in older adults. Progressive weakness of one or both upper and lower limbs, gait disturbance, and aphasia may occur. Fluctuation in the level of consciousness—fluctuating changes in mental status (fluctuating level of consciousness)—is also characteristic.

In acute subdural hematoma, headache begins suddenly and consciousness declines rapidly. Hemiparesis, pupillary abnormalities, and signs of brain herniation may appear. In nontraumatic epidural hematoma as well, sudden headache, decreased consciousness, and focal neurological deficits occur, but it is less frequent. In SDH due to intracranial hypotension, the characteristic feature of headache that clearly worsens on standing (orthostatic headache) and is relieved by lying down is a diagnostic clue. In elderly patients without a history of trauma who have subacute or chronic cognitive changes and headache, CSDH should always be included in the differential diagnosis.


7. Signs

On physical examination, signs of nontraumatic intracranial hemorrhage are evaluated systematically.

Neurological signs: hemiparesis contralateral to the side of brain compression by the hematoma is the most common focal neurological sign. Rarely, the Kernohan's notch phenomenon, in which hemiparesis appears on the same side as the hematoma (ipsilateral), can occur (caused by compression of the contralateral cerebral peduncle against the tentorium due to brain herniation). Aphasia may occur with hematomas adjacent to the dominant hemisphere. Cognitive decline, decreased concentration, and behavioral changes are prominent with bilateral hematomas or hematomas near the frontal lobe.

Pupillary abnormalities—ipsilateral pupillary dilation and loss of the light reflex—are a highly urgent sign of impending uncal herniation. Papilledema may be found on funduscopic examination when intracranial pressure is markedly elevated. When headache that worsens on standing is accompanied by neck pain and horizontal diplopia (abducens nerve palsy), the possibility of SDH due to intracranial hypotension is considered. In patients with coagulation disorders, signs of a systemic bleeding tendency such as cutaneous ecchymoses, mucosal bleeding, and joint bleeding may be present. In some cases, the motor response on the side of the hematoma is better than on the opposite side, or hemiparesis is not clear and only gait disturbance is prominent.


8. Screening

Rapid screening is important when nontraumatic intracranial hemorrhage is suspected.

Non-contrast brain CT is the first-line screening test. Subdural hematoma appears on CT as a characteristic crescent-shaped distribution of blood along the brain surface. The age of the hematoma is distinguished by CT density: acute SDH (hyperdense, 1–3 days), subacute SDH (isodense, 4–21 days), chronic SDH (hypodense, > 21 days). In bilateral SDH, isodense hematomas may be difficult to detect on CT, and effacement of the sulci and compression of brain structures despite the absence of midline shift are clues.

Blood tests include complete blood count, coagulation (PT-INR, aPTT, platelets), renal function, liver function, and blood glucose to evaluate coagulation abnormalities and underlying causes. Whether and which anticoagulants are being taken is confirmed. When intracranial hypotension is suspected, after confirming that intracranial pressure is not sufficiently low, brain/spinal MRI is performed to evaluate the site of CSF leakage. In elderly patients who are easily misdiagnosed with dementia or normal pressure hydrocephalus, it is important to actively exclude SDH with brain CT when headache, gait disturbance, or cognitive changes occur.


9. Diagnosis

After an I62 lesion is confirmed on non-contrast CT, further evaluation is performed.

Brain MRI evaluates the internal structure of the hematoma more accurately than CT and shows excellent sensitivity especially in subacute SDH (difficult to detect on CT as it is isodense). High signal on FLAIR, high signal on T1-weighted images (methemoglobin), mixed signal on T2-weighted images, and the presence of accompanying ischemia on DWI are evaluated. Septation within the hematoma, rebleeding layers (layering), and double membranes are identified and used for surgical planning.

In spontaneous SDH of unknown cause, vascular malformations such as dural AVF, cerebral aneurysm, and AVM are excluded with CT angiography (CTA) or DSA. When intracranial pressure is low, the site of CSF leakage is identified with spinal MRI and CT myelography to evaluate intracranial hypotension-related SDH. The ABC/2 method or 3D CT volumetry is used to calculate hematoma size, and the surgical indication is judged by combining thickness, volume, and midline shift. If necessary for analysis of coagulation causes, platelet function tests and coagulation factor tests are additionally performed.


10. Treatment

Acute-phase intensive care for nontraumatic intracranial hemorrhage (I62) (V268: intensive care unit admission) is determined by hematoma type and severity.

Surgical drainage is the standard treatment for symptomatic hematomas. In chronic subdural hematoma, burr-hole drainage is the most commonly performed surgery, in which one or two holes are made in the skull under local or general anesthesia to drain the hematoma. The success rate is about 85–90%, and the complication rate is low. Craniotomy is performed for thick hematoma membranes, calcified hematomas, and recurrent hematomas. Minimally invasive endoscopic surgery is used at some centers. Middle meningeal artery embolization (MMA embolization) is increasingly used to prevent recurrence after surgery, as an alternative for high-risk surgical patients, or as a surgical adjunct, and its effect in preventing recurrence is being confirmed in studies such as the 2024 EMBOLIZE study.

Dexamethasone is used as nonsurgical treatment or postoperative adjunctive therapy because of its suppression of neovascularization of the hematoma membrane and its anti-inflammatory effect. Studies such as DRESH (2021, JAMA) confirmed that dexamethasone is effective in promoting spontaneous absorption in asymptomatic, small hematomas, but caution is needed regarding adverse effects such as diabetes. In acute SDH, emergency surgery is recommended when the hematoma is thick (over 10 mm) and midline shift exceeds 5 mm. Coagulation reversal (in anticoagulant-related bleeding) follows the same principles as I61. In SDH related to intracranial hypotension, the SDH may improve with an epidural blood patch at the site of CSF leakage.


11. Prognosis

The prognosis of nontraumatic subdural hematoma (I62) differs greatly according to hematoma type and preoperative neurological status.

Chronic subdural hematoma has a relatively favorable prognosis when treated in a timely manner. The proportion achieving functional recovery (mRS 0–2) after burr-hole drainage is about 70–90%, and surgery-related mortality is about 1–5%. However, the recurrence rate is substantial at about 10–20%, and the risk of recurrence is high especially with continued anticoagulant use, advanced age, bilateral hematomas, and severe brain atrophy. Imaging follow-up within 1–3 months after surgery is recommended, and reoperation or MMA embolization is considered for recurrence.

Acute subdural hematoma has a poor prognosis, and the mortality of nontraumatic acute SDH is also considerable. The mortality of acute SDH with GCS ≤8 and a thick hematoma is about 40–50%. Nontraumatic epidural hematoma is very rare, so prognostic data are limited, but substantial recovery is possible with correction of coagulopathy and appropriate surgery. In SDH related to intracranial hypotension, most SDHs are spontaneously absorbed after the CSF leak is corrected, and the prognosis is good. Across I62 patients, the initial neurological status (GCS, hematoma size, midline shift) is the strongest predictor of prognosis.


12. Prevention

Prevention of nontraumatic intracranial hemorrhage (I62) requires a cause-specific approach.

Appropriate anticoagulant management is the most important means of prevention. In patients using warfarin, regular monitoring to maintain the INR within the therapeutic range (2.0–3.0) is essential. When prescribing DOACs, selection of an appropriate dose (based on renal function) and attention to drug interactions are needed. Care is taken not to unnecessarily combine antiplatelet agents in patients taking anticoagulants. Fall prevention is especially important in elderly patients. It includes assessment of fall risk factors, improvement of the home safety environment, balance and strength training, treatment of orthostatic hypotension, and review of polypharmacy (dose reduction of sedatives and hypnotics). In elderly patients taking anticoagulants, fall prevention is essential not only to prevent intracranial hemorrhage but also to prevent other bodily injuries. In intracranial hypotension, when the causative lesion (spinal CSF leak) is found, recurrent SDH is prevented with an epidural blood patch or surgical correction. MMA embolization to prevent recurrence after CSDH surgery is currently at the stage of accumulating evidence. In patients with coagulation disorders, appropriate coagulation factor replacement and treatment of the underlying disease are important for preventing spontaneous intracranial hemorrhage.


13. References

  1. Edlmann E, Giorgi-Coll S, Whitfield PC, et al. Pathophysiology of chronic subdural haematoma: inflammation, angiogenesis and implications for pharmacological treatment. J Neuroinflammation. 2017;14(1):108. DOI: 10.1186/s12974-017-0881-6. PMID: 28549481.

  2. Miah IP, Tank Y, Rosendaal FR, et al. Dexamethasone therapy versus surgery for chronic subdural haematoma (DRESH study): a randomised, open-label, parallel-group trial. JAMA Neurol. 2021;78(8):983-992. DOI: 10.1001/jamaneurol.2021.1751. PMID: 34100003.

  3. Gaetani P, Tartara F, Tancioni F, et al. Deficiency of activity of gamma-glutamyl transpeptidase in chronic subdural haematoma fluid. J Neurol Sci. 1995;134(1-2):44-48. DOI: 10.1016/0022-510X(95)00219-K. PMID: 8719036.

  4. Link TW, Boddu S, Paine SM, et al. Middle meningeal artery embolization for chronic subdural hematoma: a series of 60 cases. Neurosurgery. 2019;85(6):801-807. DOI: 10.1093/neuros/nyy521. PMID: 30521029.

  5. Nakaguchi H, Tanishima T, Yoshimasu N. Factors in the natural history of chronic subdural hematomas that influence their postoperative recurrence. J Neurosurg. 2001;95(2):256-262. DOI: 10.3171/jns.2001.95.2.0256. PMID: 11780895.

  6. Holl DC, Volovici V, Dirven CMF, et al. Pathophysiology and nonsurgical treatment of chronic subdural hematoma: from past to present to future. World Neurosurg. 2018;116:402-411. DOI: 10.1016/j.wneu.2018.05.096. PMID: 29800790.

  7. Ducruet AF, Grobelny BT, Zacharia BE, et al. The surgical management of chronic subdural hematoma. Neurosurg Rev. 2012;35(2):155-169. DOI: 10.1007/s10143-011-0349-y. PMID: 21882039.

  8. Schievink WI. Spontaneous spinal cerebrospinal fluid leaks and intracranial hypotension. JAMA. 2006;295(19):2286-2296. DOI: 10.1001/jama.295.19.2286. PMID: 16705110.

  9. Ban SP, Hwang G, Byoun HS, et al. Middle meningeal artery embolization for chronic subdural hematoma. Radiology. 2018;286(3):992-999. DOI: 10.1148/radiol.2017170143. PMID: 29053408.

  10. Kolias AG, Chari A, Santarius T, Hutchinson PJ. Chronic subdural haematoma: modern management and emerging therapies. Nat Rev Neurol. 2014;10(10):570-578. DOI: 10.1038/nrneurol.2014.163. PMID: 25224156.